CD28-Directed T Cell Costimulation Blockade with Abatacept to Prevent GVHD During High-Risk Unrelated HSCT: A First-In-Disease Trial  by Kean, L.S. et al.
Poster Session II S365animals with cGVHD, with the CD4+ population having a 13-
fold reduction compared to syngeneic controls. By cell surface
phenotype, the recent thymic emigrant (RTE) CD4 proportion
(CD4+ CD44lo CCR7+ CD69-) was most severely affected, dem-
onstrating a 100-fold reduction. The spleens of affected animals
were enriched for memory T cells, particularly T effector mem-
ory (CD4+ or CD8+ CD44 high CCR7-). Furthermore, the ef-
fector memory T splenocytes of mice with cGHVD were more
likely to have an activated phenotype as evidenced by CD69 ex-
pression. Congenic AHSCT confirmed that the splenic CD4+
compartment was donor-derived. The total number of splenic
T regulatory cells (CD4hi Foxp3+ CD25+) was diminished in an-
imals with cGVHD; however, the proportion of this subset was
increased in the cGVHD mice. The T reg compartment was
also donor peripherally derived. These data show that cGVHD
is associated with impaired thymopoiesis. The relative CD4 lym-
phopenia and diminished RTE numbers likely stem from im-
paired thymic output and are associated with donor-derived
peripherally expanded CD4+ cell predominance.436
CD28-DIRECTED T CELL COSTIMULATION BLOCKADE WITH ABATACEPT
TO PREVENT GVHD DURING HIGH-RISK UNRELATED HSCT: A FIRST-IN-
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We describe a first-in-disease trial of CD28-directed costimu-
lation blockade to prevent GvHD after URD HSCT in patients
.12y with advanced heme malignancies (Clinical Trials.Org
#NCT01012492). In this trial, 10 mg/kg abatacept is adminis-
tered on d -1, +5, +14, and +28 in addition to standard GvHD
prophylaxis (cyclosporine + methotrexate). 10 of 11 planned pa-
tients have enrolled, of which 8 are evaluable for engraftment
and toxicity, and 5 are evaluable for the primary immunologic
outcome of the study: the incidence of steroid-requiring GvHD
at d+100 post-transplant. The median patient age is 46 y (17-
74 y). 5 transplants were 7/8 HLA matched and 3 were 8/8
matched. 7 of the 8 patients are currently alive and in remission.
1 patient relapsed at d+98 (and died on d+121 with refractory
AML). The other 7 patients are surviving without relapse with
a follow-up of 57-377d.
All 8 patients received the 4 scheduled abatacept doses, without in-
fusional side-effects. All patients achieved neutrophil engraftment
(median d+19) and donor engraftment (100% CD33 chimerism at
d+30). Of the five post- d+100 patients, all demonstrated rapid lym-
phocyte engraftment (mean ALC.500 cells/mL by d+21). At d+100,
their mean CD3+, CD8+ and CD4+ T cell counts were 673 +/- 251,
384 +/- 148, and 229 +/- 119 cells/mL, respectively. T cell reconsti-
tution was accompanied by a shift toward a CCR7-/CD45RA- effec-
tor memory (Tem) phenotype, with CD4+ Tem increasing from 22
+/- 6% pre-transplant to 46 +/- 7%, and CD8+Tem increasing from
15 +/- 4% pre-transplant to 32 +/- 7%, both with a reciprocal de-
crease in Tnaive cells.
At the d+100 primary end-point, only 1 of the 5 evaluable patients
on the abatacept trial developed steroid-requiring GvHD. 3 addi-
tional patients are \100 days post-transplant (between d+57-64),
and none has developed GvHD. In striking contrast, in a contempo-
raneously transplanted cohort of 5 patients enrolled on an immune
monitoring protocol (and who had the same disease indications
and transplant preparative regimens, but who received standard
GvHD prophylaxis), 4 of 5 of these patients developed steroid-re-
quiring GvHD before d+100. 2 patients required salvage therapy
and one patient died from GvHD.
These preliminary data suggest that abatacept can be safely added
to cyclosporine and methotrexate for GVHD prophylaxis during
URD HSCT, with encouraging rates of GVHD at the d+100 pri-
mary endpoint. As such, they support the conduct of a larger, ran-
domized phase 2 study.437
NILOTINIB (TASIGNA) THERAPY POST ALLOGENEIC STEM CELL TRANS-
PLANTATION (ALLoSCT) FOR ADVANCED (.CP1) CHRONIC MYELOID
LEUKEMIA (CML) AND PH+ ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Nagler, A., Volchek, Y., Varda-Bloom, N., Somech, R., Yerushalmi, R.,
Shimoni, A. Chaim Sheba Medical Center, Ramat Gan, Israel
Relapse rate post alloSCT in advanced CML (.CP1) and in Ph+
ALL is high. We assessed (study CAN107AIL03T) whether Niloti-
nib administration post alloSCT intensifies remission and reduce re-
lapses. 24 pts (M-13, F-11), age 36 years (range, 18-58) participated
in the study. 17 pts were with advanced CML (BC-10, AP-7) and 7
with Ph+ ALL. 22/24 pts underwent alloSCT (2 are pending) from
an HLA-matched sibling (n5 11), matched unrelated (n 5 8) or al-
ternative donor (CB-2, Haplo-1). All, but one, had myeloablative
conditioning (Bu/Cy or Flu/Bu-14, TBI/Cy-7). GVHD prophylaxis
includedCSA andmethotrexate orMMF. 21/22 pts engrafted inme-
dian day+13 (range, 9-38) with 100% donor chimerism. TRT in-
cluded mucositis in all pts, encephalitis-2, pericarditis-1, VOD-1
and infection-3. 3 pts died very early post transplant from sepsis
and multi organ failure. Acute GVHD $ Gr II was observed in 10
pts (III-IV in 5). cGVHD was observed in 15 pts (extensive – 9).
16/22 transplanted pts received Nilotinib (200mg x 2/d – 10,
300mg x 2/d – 6) starting at median day +38 (range, 30-158) post al-
loSCT. 6 pts did not receive Nilotinib post alloSCT due to early
death -3, progressive disease -1, severe pancytopenia -1, refusal -1.
Nilotinib administration was delayed or dose reduced/stopped in 9
and 7 pts, respectively due to toxicities. All, but 2 pts achieved
MMR post alloSCT and 6 of them (CML) converted to CMR fol-
lowing Nilotinib therapy. Kinas mutation (G205E and F359V)
were detected only in 1 pt with disease progression. With a median
follow up of 16.5 mo (range, 2.5-38) 12 pts are alive while 12 died
(Infection -5, GVHD -3, TTP-1, disease progression -3). In 2 pts
disease progressed but responded to further therapy. All 6 pts that
did not receive Nilotinib died (early death post allo-SCT -3, disease
progression -1, GVHD Gr IV -2). Immunological evaluation post
Nilotinib administration disclosed no significant change in T, B
andNK cell numbers and T cell mitogenic response. Thymic output
(TREC) and receptor repertoire (Spectrotyping) analysis indicates
continuous thymopoiesis in 8/13 evaluated pts. NK cytotoxic activity
against K562 increased in 9/15 evaluated pts. In conclusion, post al-
loSCT Nilotinib maintenance therapy in extremely high risk pts
with advanced CML and Ph+ ALL may prevent relapse and disease
progressionand should be recommend as 1) pts achievedMMR and 6
converted to CMR with Nilotinib therapy and 2) only 5/16 pts that
received Nilotinib post alloSCT progressed.438
ALEMTUZUMAB FOR STEROID REFRACTORY ACUTE GRAFT VERSUS HOST
DISEASE IN PEDIATRIC PATIENTS: A RETROSPECTIVE REVIEW OF 12 PA-
TIENTS REVEALS A RESPONSE RATE OF 83%
Khandelwal, P., Filipovich, A.H., Mehta, P., Jodele, S., Grimley, M.S.,
Myers, K., Jordan, M.B., Kumar, A., Bleesing, J.J., Davies, S.M.,
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High dose steroids are themainstay of treatment of acute graft ver-
sus host disease (GVHD) with a response rate of 30-70%. A clear
second line agent for steroid refractory graft versus host disease
has not been established and it remains a significant cause of morbid-
ity and mortality in allogeneic hematopoietic cell transplant (HCT)
recipients. In order to estimate the effectiveness of alemtuzumab for
the treatment of steroid refractory acute GVHD in pediatric pa-
tients, we retrospectively reviewed the charts of 12 patients (median
age 6.5years, range 1.25-21years) with grades II (n 5 1), III (n5 6),
or IV (n 5 5) steroid refractory acute GVHD who received alemtu-
zumab for treatment. Steroid refractory acute GVHDwas defined as
progression of GVHD after 48 hours of./5 2 mg/kg steroid treat-
ment, or lack of response within 5 days. Patients received a median
dose of 0.73mg/kg alemtuzumab (range 0.3-2mg/kg) divided over
2-5 days. Seventy-five percent of patients received repeated courses.
A complete response, defined asGVHDof grade 0 at 4 weeks follow-
ing the first alemtuzumab course, was observed in 7 patients (58%). A
partial response, defined as a grade improvement after 4 weeks, was
